Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Board Meeting Date

Lupin Board Meeting Date

Lupin Limited scheduled a Board meeting on November 03, 2026, to consider and approve its unaudited standalone and consolidated financial results.

Source

BSE filing, NSE: LUPIN. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Lupin Ltd: key numbers

Share price
₹1,972.70
Market cap
₹90,210 Cr
Revenue (annual)
₹27,958 Cr
Net profit (annual)
₹5,333 Cr
P/E (TTM)
16.3×Sector 46.1×
Promoter holding
46.84%-0.01% QoQ
FII holding
23.28%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Lupin Ltd

All →
20:58 IST BSE
Regulatory Approval

Lupin Regulatory Approval

Lupin Limited received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Phytonadione Injectable Emulsion, USP (1 mg/0.5 mL single-dose prefilled syringe).

09:36 IST BSE
Product Launch

Lupin Product Launch

Lupin Limited launched Formoflo-G® MDI, the world's first fixed-dose triple combination inhaler for COPD management in India. This follows approval from the Drug Controller General of India.

Other board meeting date announcements

All →